Behavioural and physiological measures of the effects of dopamine on attention in Parkinson*s disease

Behavioural and physiological measures of the effects of dopamine on attention in Parkinson*s disease - PD and the role of dopamine in attention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34140

Enrollment

Registered

2010-10-27

Start date

2011-02-28

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease PD

Interventions

Levodopa administration after overnight withdrawal.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis of idiopathic PD following UK Brain Bank criteria in Hoehn and Yahr stages2-3 40-75 years old informed consent On DA replacement therapy

Exclusion criteria

Exclusion criteria: psychotropic medication other than DA therapy (at least 4 weeks off medication) major somatic disorder or known psychiatric diagnosis Dementia (MMSE

Design outcomes

Primary

Measure	Time frame
Outcome parameters are: behavioural measures of response latency and accuracy and non-invasive electrophysiological measures in the form of event-related potentials.	—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)